terican

Last verified · v1.0

Calculator · health

Hydroxychloroquine Maximum Daily Dose Calculator

Calculate maximum hydroxychloroquine daily dose by body weight using AAO 2016, legacy, or conservative dosing guidelines.

FreeInstantNo signupOpen source

Inputs

Maximum Daily Dose

—

Explain my result

0/3 free

Get a plain-English breakdown of your result with practical next steps.

Maximum Daily Dose—mg

The formula

How the
result is
computed.

How the Hydroxychloroquine Maximum Daily Dose Calculator Works

Hydroxychloroquine (HCQ), sold under the brand name Plaquenil, is a disease-modifying antirheumatic drug (DMARD) prescribed for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and other autoimmune conditions. Determining the correct maximum daily dose is critical because cumulative overdosing is the primary modifiable risk factor for hydroxychloroquine-induced retinopathy — an irreversible eye condition that can lead to permanent vision loss. This hydroxychloroquine dose calculator implements three evidence-based dosing methods derived from landmark clinical guidelines and peer-reviewed research.

The Three Dosing Methods Explained

AAO 2016 Guideline (Current Recommended Standard)

The American Academy of Ophthalmology 2016 Revised Recommendations, authored by Marmor et al. and published in Ophthalmology, established the current clinical standard of care. This guideline caps the daily dose at 5.0 mg per kg of actual body weight (ABW).

  • Formula: Max Daily Dose (mg) = 5.0 × ABW (kg)
  • Example: A patient weighing 70 kg has a maximum daily dose of 5.0 × 70 = 350 mg/day.
  • The 2016 revision replaced the prior threshold of 6.5 mg/kg IBW after epidemiological studies revealed hydroxychloroquine retinopathy affects up to 7.5% of patients on long-term therapy exceeding 5 years — a prevalence far higher than earlier estimates recognized.

Legacy Guideline (Pre-2016, FDA Label Reference)

Before 2016, the standard dosing ceiling was 6.5 mg per kg of ideal body weight (IBW), as referenced in the FDA Plaquenil prescribing label. IBW is calculated using the Devine formula, which adjusts for biological sex and height.

  • Male IBW: 50 + 2.3 × (height in inches − 60) kg
  • Female IBW: 45.5 + 2.3 × (height in inches − 60) kg
  • Example: A 165 cm (approximately 65 inches) female has an IBW of 45.5 + (2.3 × 5) = 57.0 kg, giving a legacy maximum dose of 6.5 × 57.0 = 370.5 mg/day.
  • Though still present in the FDA label, this method is no longer the recommended safety benchmark for retinopathy prevention under current ophthalmological guidance.

Conservative Method (Most Protective)

The conservative method applies the AAO 2016 rate of 5.0 mg/kg to the lower of actual body weight (ABW) or ideal body weight (IBW), providing the most protective dose ceiling available in this calculator.

  • Formula: Max Daily Dose (mg) = 5.0 × min(ABW, IBW)
  • This approach is particularly relevant for overweight and obese patients, where ABW can greatly exceed IBW, and where basing the dose on ABW alone may overestimate safe retinal drug exposure relative to lean body mass.
  • Example: A patient with ABW of 95 kg and IBW of 60 kg yields a conservative maximum dose of 5.0 × 60 = 300 mg/day.

The Devine Ideal Body Weight Formula

The Devine formula, originally published in 1974 and extensively validated in pharmacokinetic dosing research, converts patient height into a sex-adjusted lean weight estimate. Height is converted from centimeters to inches by dividing by 2.54. For patients under 152.4 cm (60 inches), the formula defaults to the base value (50 kg for males, 45.5 kg for females) without applying the height-additive term.

Worked example — 175 cm male: IBW = 50 + 2.3 × ((175 ÷ 2.54) − 60) = 50 + 2.3 × 8.86 ≈ 70.4 kg

Clinical Context and Retinopathy Risk

Research published by Petri (2016) in PMC — Solving the Hydroxychloroquine Dosing Dilemma demonstrated that switching from the legacy IBW-based formula to ABW-based dosing meaningfully reduces dose exposure in overweight patients — the population where the two weight values diverge most. Effective disease control in lupus and rheumatoid arthritis remains achievable at the lower ABW-based ceiling, making the safety trade-off clinically favorable for the vast majority of patients.

Additional Dosing Considerations

  • Renal impairment: Dose reductions are typically warranted when creatinine clearance falls below 30 mL/min, as hydroxychloroquine undergoes significant renal elimination.
  • Cumulative dose threshold: A lifetime cumulative dose exceeding 1,000 g represents an independent risk factor for retinopathy, regardless of daily dose adherence.
  • Ophthalmologic screening: The AAO recommends a baseline eye examination within the first year of therapy and annual screening after 5 years of continuous use.
  • Tablet rounding: Standard hydroxychloroquine sulfate tablets are 200 mg; calculated doses are typically rounded to the nearest 200 mg increment in clinical practice.

Reference

Frequently asked questions

What is the AAO 2016 recommendation for hydroxychloroquine daily dosing?
The American Academy of Ophthalmology 2016 guideline, established by Marmor et al., recommends a maximum hydroxychloroquine dose of 5.0 mg per kg of actual body weight per day. This replaced the older 6.5 mg/kg IBW threshold after studies revealed retinopathy affects up to 7.5% of patients on long-term therapy — a prevalence far higher than previously estimated, making the stricter weight-based cap essential for protecting long-term visual health in all patients on sustained therapy.
How is ideal body weight calculated for hydroxychloroquine dosing?
Ideal body weight for hydroxychloroquine dosing uses the Devine formula. For males: IBW = 50 + 2.3 × (height in inches minus 60). For females: IBW = 45.5 + 2.3 × (height in inches minus 60). A 170 cm (67 inch) male has an IBW of 50 + (2.3 × 7) = 66.1 kg. Height must be converted from centimeters to inches by dividing by 2.54 before applying the formula.
What is the maximum safe daily dose of hydroxychloroquine?
Under the current AAO 2016 guideline, the maximum safe daily dose of hydroxychloroquine is 5.0 mg/kg of actual body weight. For a 70 kg patient, this equals 350 mg/day. The FDA prescribing label still references up to 400–600 mg/day for lupus, but contemporary clinical practice prioritizes the weight-based ceiling to minimize cumulative retinal drug exposure and reduce the risk of irreversible retinopathy over long-term therapy.
Which hydroxychloroquine dosing method is recommended for overweight patients?
Overweight and obese patients benefit most from the conservative dosing method, which applies 5.0 mg/kg to the lower of actual body weight (ABW) or ideal body weight (IBW). Because hydroxychloroquine does not distribute proportionally into adipose tissue, using a high ABW in obese patients can overestimate the safe dose and increase retinal drug concentration. The conservative method anchors the calculation to lean body mass when ABW exceeds IBW significantly, providing maximum retinal protection.
Why did the hydroxychloroquine dosing guideline change in 2016?
The 2016 dosing revision by the American Academy of Ophthalmology was driven by updated epidemiological data showing that hydroxychloroquine retinopathy was far more prevalent than earlier estimates suggested. Long-term studies found retinopathy rates of up to 7.5% after 5 years of therapy when dosed at the older 6.5 mg/kg IBW ceiling. The revised 5.0 mg/kg ABW threshold significantly lowers cumulative retinal exposure, reducing toxicity risk without sacrificing therapeutic efficacy for most patients with lupus or rheumatoid arthritis.
What are the risks of exceeding the recommended hydroxychloroquine dose?
Exceeding the recommended hydroxychloroquine dose substantially increases the risk of retinopathy — an irreversible condition characterized by bull's-eye maculopathy and permanent central vision loss. Studies indicate that patients consistently dosed above 5 mg/kg/day face cumulative retinopathy rates exceeding 20% after 20 years. Early toxicity is often asymptomatic and only detectable via visual field testing or spectral-domain OCT, making strict dose adherence and annual ophthalmologic screening essential for all long-term users.